TSGF和CYFRA21-1联合检测在乳腺癌中的应用

目的探讨联合检测血清肿瘤相关物质群(TSGF)和CYFRA21-1的水平在乳腺癌的诊断、疗效观察中的价值。方法45例乳腺癌患者及健康对照48人的血清样品,分别用化学比色定量法和电化学发光免疫测定法测定TSGF和CYFRA21-1含量。结果与健康对照组相比,乳腺癌患者血清TSGF和CYFRA21-1的含量明显升高(P<0.05),2项标志物的阳性检出率分别是46.7%和24.4%,二者联合检测阳性率为60.0%,晚期乳腺癌患者TSGF和CYFRA21-1水平明显高于早期患者,乳腺癌患者血清TSGF和CYFRA21-1水平在治疗后与治疗前相比,有显著差异(P<0.05)。结论血清TSGF和CYFRA21-1对乳腺癌的诊断具有一定应用价值,联合检测不仅可以提供乳腺癌的阳性诊断率,对乳腺癌的疗效观察和术后监测也具有重要价值。

Clinical value of combined detection of TSGF and CYFRA21-1 in the diagnosis of breast cancer

Objective To study the clinical value of combined detection of the serum levels of tumor supplies group of factors (TSGF) and CYFRA21-1 in the diagnosis of breast cancer and the observation of the curative effect. Methods Serum levels of TSGF and CYFRA21-1 in 45 patients with breast cancer and 48 normal controls were measured by chemical colorimetry and Elctrochemiluminescence immuno-assay (ECLIA). Results The levels of CYFRA21-1 and TSGF in breast cancer group were significantly higher than those in normal control groups(P<0.05). Sensitivities of TSGF and CYFRA21-1 were 46.7% and 24.4%, respectively. Sensitivity of combined detection of two kinds tumor markers was 60.0%. The levels of CYFRA21-1 and TSGF in advanced stage mannary cancer was higher than that in premature mammary cancer, and the levels of CYFRA21-1 and TSGF in patients with breast cancer were significantly different after treatment(P<0.05). Conclusions The serum levels of TSGF and CYFRA21-1 are helpful in diagnosis of breast cancer. Combined detection of two kinds of serum tumor makers not only increases the detective positive rate but also is valuable to observe the curative rate and postoperative monitor of the breast cancer.